Axial3D
AI-powered medical imaging platform that automatically converts 2D medical scans into precise, patient-specific 3D models for surgical planning and diagnostic use.
- CEO / Founder
- Roger Johnston (confirmed CEO as of 2024)
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $36.2M
- Latest Round
- Series C ($18.2M, Dec 2024)
- Key Investors
- 57 Stars ($10M lead), Stratasys ($10M lead), Whiterock, Innovate UK, Techstart Ventures, Clarendon Fund Managers, Imprimatur Capital Fund Management, Innovation Ulster Limited, US surgical angel investors
Technology & Products
Key Products
AI-powered 3D medical imaging platform that automatically converts DICOM data (CT, MRI, PET) into patient-specific 3D anatomical models for surgical planning, device development, and clinical decision-making.
Technological Advantage
The company's key advantage is its FDA-cleared, patented AI technology that ensures rapid and accurate segmentation. This is complemented by a strategic partnership with Stratasys, providing access to advanced 3D printing technology and a global distribution network.
Differentiation
Value Proposition
To make patient-specific surgical planning routine and accessible by providing automated, fast, and accurate 3D anatomical models, leading to improved surgical outcomes and reduced costs.
How They Differentiate
Axial3D differentiates itself through its focus on a highly automated, AI-powered software platform that integrates seamlessly into clinical workflows. This software-first approach, combined with its strategic partnership with Stratasys for printing, allows for greater scalability and accessibility compared to competitors who may have a more service-oriented or machine-focused business model.
Market & Competition
Target Customers
Hospitals, surgeons, and medical device manufacturers.
Industry Verticals
["Healthcare"]
Competitors
Materialise; 3D Systems; Ricoh 3D for Healthcare
Growth & Milestones
Growth Metrics
While specific revenue figures are not public, the company's significant and successful funding rounds, strategic partnerships, and FDA clearance indicate strong growth and market traction.
Major Milestones
["Received FDA 510(k) clearance for its Axial3D INSIGHT™ medical image segmentation platform.","Secured a $15 million funding round, including a $10 million strategic investment from Stratasys.","Announced a further $18.2 million investment to scale its AI-powered technology and expand its US presence."]
Notable Customers
Belfast City Hospital (used Axial3D's models to clear a kidney transplant backlog during the COVID-19 pandemic)